Procalcitonin as a Marker of Serious Bacterial Infections in Febrile Children Younger Than 3 Years Old by Mahajan, Prashant et al.
ORIGINAL RESEARCH CONTRIBUTION
Procalcitonin as a Marker of Serious Bacterial
Infections in Febrile Children Younger Than
3 Years Old
Prashant Mahajan, MD, MPH, MBA, Mary Grzybowski, PhD, MPH, Xinguang Chen, MD, PhD,
Nirupama Kannikeswaran, MD, Rachel Stanley, MD, MHSA, Bonita Singal, MD, John Hoyle, Jr., MD,
Dominic Borgialli, MD, MPH, Elizabeth Duffy, MA, and Nathan Kuppermann, MD, MPH
Abstract
Objectives: There is no perfectly sensitive or speciﬁc test for identifying young, febrile infants and
children with occult serious bacterial infections (SBIs). Studies of procalcitonin (PCT), a 116-amino-acid
precursor of the hormone calcitonin, have demonstrated its potential as an acute-phase biomarker for
SBI. The objective of this study was to compare performance of serum PCT with traditional screening
tests for detecting SBIs in young febrile infants and children.
Methods: This was a prospective, multicenter study on a convenience sample from May 2004 to
December 2005. The study was conducted in four emergency departments (EDs): one pediatric ED and
three EDs with pediatric units, all with academic faculty on staff. A total of 226 febrile children
36 months old or younger who presented to the four participating EDs and were evaluated for SBI by
blood, urine, and/or cerebral spinal ﬂuid (CSF) cultures were included.
Results: The test characteristics (with 95% conﬁdence intervals [CIs]) of the white blood cell (WBC)
counts including neutrophil and band counts were compared with PCT for identifying SBI. Thirty
children had SBIs (13.3%, 95% CI = 8.85 to 17.70). Four (13.3%) had bacteremia (including one with
meningitis), 18 (60.0%) had urinary tract infections (UTIs), and eight (26.6%) had pneumonia. Children
with SBIs had higher WBC counts (18.6 9 109  8.6 9 109 cells/L vs. 11.5 9 109  5.3 9 109 cells/L,
p < 0.001), higher absolute neutrophil counts (ANCs; 10.6 9 109  6.7 9 109 cells/L vs. 5.6 9 109 
3.8 9 109 cells/L, p = 0.009), higher absolute band counts (0.90 9 109  1.1 9 109 cells/L vs. 0.35 9 109 
0.6 9 109 cells/L, p = 0.009), and higher PCT levels (2.9  5.6 ng/mL vs. 0.4  0.8 ng/mL, p = 0.021) than
those without SBIs. In a multivariable logistic regression analysis, the absolute band count and PCT were
the two screening tests independently associated with SBI, although the area under the receiver
operating characteristic (ROC) curve for PCT was the largest (0.80, 95% CI = 0.71 to 0.89).
Conclusions: Procalcitonin is a more accurate biomarker than traditional screening tests for identifying
young febrile infants and children with serious SBIs. Further study on a larger cohort of young febrile
children is required to deﬁnitively determine the beneﬁt of PCT over traditional laboratory screening
tests for SBIs.
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Fever is a common symptom in children youngerthan 3 years of age presenting to the emergencydepartment (ED). Most children with fever with-
out source will have nonbacterial causes of fever that will
resolve without intervention.1 Some febrile children,
however, will have occult serious bacterial infections
(SBIs) such as bacteremia, urinary tract infections (UTIs),
bacterial meningitis, lobar pneumonia, or bacterial enter-
itis. Because several investigations have demonstrated
that the clinical examination by itself is not a reliable
method to identify children with SBIs, clinicians depend
on various risk stratiﬁcation strategies that use screening
laboratory tests. For the youngest infants, those younger
than 3 months, three commonly used strategies include
the Rochester, Philadelphia, and Boston screening crite-
ria.1 For infants 3 months to 36 months of age, other
screening strategies have been used, although the use,
accuracy, and reliability of these screening methods have
changed since the introduction of the conjugate pneumo-
coccal vaccine.2 Although the screening strategies for
both younger and older infants aim to identify most
children with SBIs, the economic costs and effect on clin-
ical efﬁciency of extensive routine laboratory evaluation,
including potential iatrogenic morbidity, have been
debated to a great extent.3 As of yet, there is no perfectly
sensitive or speciﬁc test for identifying young, febrile
children with occult SBIs, although several research
studies and reviews have suggested the addition of
speciﬁc biomarkers, including C-reactive protein (CRP)
and interleukins (ILs; IL-6, IL-1, and IL-8) to routine
screening tests in young febrile children.4
Much research has focused on evaluating screening
tests and biomarkers that would allow the clinician to
reliably and efﬁciently discriminate febrile children with
occult SBIs from those with viral infections. Studies of
procalcitonin (PCT), a 116-amino-acid precursor of the
hormone calcitonin, have demonstrated its potential as
an acute-phase biomarker for SBI.5–9
Since the ﬁrst report of the association between
serum PCT and sepsis,10 several other studies have
demonstrated that serum PCT levels rise more rapidly
in bacterial infections when compared with CRP and
other biomarkers such as the ILs. Furthermore, serum
PCT levels correlate with severity of disease and mortal-
ity.4,5 However, the marginal beneﬁt of using serum
PCT to screen young febrile children for SBIs above
and beyond routine screening tests has not been deﬁni-
tively elucidated. The primary goal of this study was to
determine whether serum PCT is a more accurate
screening biomarker for detecting SBI in febrile infants
and young children without obvious source who pres-
ent to the ED, compared to traditional screening tests
such as the white blood cell (WBC) count, absolute
neutrophil count (ANC), and absolute band counts.
METHODS
Study Design
This was a prospective, multicenter cross-sectional
study. The institutional review boards of all participat-
ing hospitals approved this study.
Study Setting and Population
We enrolled a convenience sample of well-appearing
febrile children without obvious source 36 months old
or younger who presented to four participating EDs
between May 2004 and December 2005. All such chil-
dren with documented fever (deﬁned as rectal tempera-
ture measured in the ED or at home of ≥38°C if
≤3 months of age and ≥39°C if >3 months of age) and
who were otherwise being evaluated for SBI, and were
documented to be well-appearing, were eligible for
enrollment. Children were excluded if they had received
antibiotics within 48 hours of ED presentation, had
obvious sources for fever (e.g., cellulitis; otitis media,
however, was not considered an exclusion criterion),
had known immunologic or systemic diseases, had his-
tories of prematurity in febrile infants younger than
3 months (≤36 weeks of gestation), had received any
immunization during the previous 2 days, or if the
guardians/parents did not provide informed consent.
Febrile infants and children who did not have blood cul-
tures obtained as a part of SBI evaluations were ineligi-
ble for enrollment. At the initiation of the study, we
conducted training sessions for all site investigators,
research assistants, and ED nurses. During these train-
ing sessions we speciﬁed that only well-appearing feb-
rile infants who were being evaluated for SBI with
blood cultures were eligible for inclusion. Additionally,
we discussed procedures for sample processing, stor-
age, and transportation at these sessions. At the end of
the study we ensured that in fact only well-appearing
febrile infants and children were included by a review
of patient medical records, searching for key words
such as “well appearing,” “non-toxic,” “alert and inter-
active,” etc.
Study Protocol
We used a structured case report form to collect
historical and clinical data at the time of patient enroll-
ment. We recorded demographic information including
age, sex, and race and ethnicity at the time of ED
evaluation. We collected the following historical vari-
ables: temperature at ED triage (rectal in centigrade),
duration of fever (in days), history of antipyretic use,
history of antibiotic use, and receipt of immunizations
within the previous 48 hours. The decision to obtain
blood for WBC counts, blood cultures, and other labo-
ratory tests (including urinalyses and cultures, cerebral
spinal ﬂuid [CSF] analyses, and chest radiographs) was
made at the discretion of the ED attending physician.
We collected an extra 1 mL of blood for a quantitative
determination of PCT and gathered information
regarding antibiotic treatment and ED disposition (dis-
charged home or admitted to the hospital). We
obtained the ﬁnal culture results from a review of each
enrolled patient’s medical record and conducted a fol-
low-up telephone interview 7 to 10 days after the index
visit to determine patient status. The PCT analyses
were performed at an outside laboratory facility at a
later time and therefore these results were not avail-
able to the clinicians at the time of patient enrollment
and evaluation.
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Laboratory Methods. The WBC count was quantiﬁed
by automated laboratory equipment using a Coulter
counter. Laboratory personnel calculated the differential
WBC manually using microscopy. Blood cultures were
processed using site-speciﬁc standardized methods.
Urine samples were obtained by catheterization of the
bladder under aseptic technique and analyzed in the
laboratory by standardized methods with microscopy.
PCT was measured by using an immunoluminometric
assay (LUMItest PCT, Brahms Diagnostica, Berlin, Ger-
many).11 To determine PCT levels, the blood samples
were centrifuged at 1700 9 g for 15 minutes to separate
the serum from the samples. The serum was then
extracted and transferred into plastic aliquot tubes and
stored in freezers with temperatures between –20 and
–80°C until the samples were ready to be shipped to an
off-site laboratory (Hemostasis Reference Laboratory,
Hamilton, Ontario, Canada) for quantitative PCT
analysis.
Measures
The primary outcome measure of the study was SBI,
deﬁned as the presence of at least one of the following:
bacteremia, bacterial meningitis, lobar pneumonia, or
UTI. We deﬁned bacteremia and bacterial meningitis as
growth of a known pathogen in blood or CSF cul-
tures.12 Growth of organisms that are not commonly
regarded as pathogens, such as Staphylococcus epide-
rmidis, a- or c-hemolytic Streptococcus, Bacillus sp., and
diphtheroids in blood or CSF, were considered to be
contaminants.12 We deﬁned a lobar pneumonia as the
presence of a focal inﬁltrate on chest radiograph as
interpreted by a pediatric radiologist or ED attending
physician. Any other ﬁndings on chest radiographs
were classiﬁed as negative for the presence of pneumo-
nia. We deﬁned UTI as the growth of a single known
pathogen with colony counts meeting one of three crite-
ria: 1) ≥1,000 CFU/mL for urine cultures obtained by
suprapubic bladder aspiration, 2) ≥50,000 CFU/mL from
a catheterized specimen, or 3) ≥10,000 CFU/mL from a
catheterized specimen in association with an abnormal
urinalysis.12 We deﬁned abnormal urinalysis as a dip-
stick test positive for leukocyte esterase or nitrite, or >5
WBCs per high-power ﬁeld on microscopic examina-
tion.13
Data Analysis
We calculated means, standard deviations (SDs), rates,
and ratios for all continuous and categorical variables,
as appropriate. For variables that were not normally
distributed we used medians and interquartile ranges.
We evaluated differences in patient characteristics strat-
iﬁed by SBI status using either Student’s t-test for para-
metric data or the Mann-Whitney U-test for
nonparametric data. We analyzed categorical data using
chi-square testing if the cell sizes were sufﬁciently large
or with Fisher’s exact test if the expected number of
observations in any cell was less than ﬁve. We calcu-
lated odds ratios (OR) with 95% conﬁdence intervals
(CIs) for bivariable associations. In addition, we
assessed diagnostic test accuracies based on suggested
thresholds from previous studies of biomarkers for SBI
and based on thresholds established by area under the
receiver operating characteristic (ROC) curve (AUC)
analyses. These biomarkers included: 1) WBC count >
15 9 109 cells/L, 2) absolute band count > 1.5 9 109
cells/L, 3) ANC >10 9 109 cells/L, and 4) serum
PCT > 0.5 ng/mL.10,14 Values above each biomarker
threshold were considered to represent positive screens
for SBI. We also constructed ROC curves for our four
continuous biomarkers to assess overall diagnostic
accuracy of each biomarker. In addition, we compared
the accuracy of PCT at a cutoff of 0.5 ng/mL with a
positive urinalysis for diagnosing UTI. Finally, to deter-
mine the marginal beneﬁt of PCT over and above com-
monly used screening tests, we performed three
multiple logistic regression analyses with SBI as the
outcome variable and using laboratory data including
PCT as continuous predictor variables, in addition to
age and body temperature. In one of these multivariable
analyses, we removed patients with positive urinalyses
(to explore the utility of PCT after removing children
with obvious UTIs). In another multivariable analysis we
removed children diagnosed with pneumonia (as the
etiology of even lobar pneumonias may at times be
viral). Because more than one continuous covariate was
modeled, the Hosmer-Lemeshow method was used with
a smaller chi-square value and a large p-value indicat-
ing a better data-model ﬁt. We constructed the multi-
variable model using the direct method and selected the
variables based on previous research literature and on
biologic plausibility. We evaluated the relationship
among all covariates and excluded collinear variables,
including the band-to-neutrophil ratio. Before the analy-
sis, we checked data quality and found no outlier values
for the predictor variables. We assumed the linear
assumption for the continuous covariates for the logistic
regression.
Sample Size. We estimated the sample size using the
null hypothesis that a PCT value of greater than 0.5 ng/
mL would be no more sensitive than a WBC greater
than 15 9 109 cells/L for diagnosing SBI. The criterion
for signiﬁcance (alpha) was set at 0.05, and with a sam-
ple size of 17 patients with SBI, the study would have a
power of 80% to yield a statistically signiﬁcant result.
This computation assumes that the difference in propor-
tions is 0.4 (speciﬁcally, 0.93 sensitivity of PCT versus
0.53 sensitivity of an elevated WBC count of 15 9 109
cells/L).7,8 Assuming a pretest probability of a SBI rate
of 10%, approximately 200 patients would need to be
enrolled.1,15
For all statistical analyses, we considered p-val-
ues < 0.05 (two-tailed) to be signiﬁcant. Except where
indicated, we performed the analyses using SAS, ver-
sion 9.1.3 (SAS Institute Inc., Cary, NC).
RESULTS
We approached the guardians of 260 febrile infants and
young children for participation in the study, of whom
226 (87%) consented, enrolled, and were included in the
analysis. Nine additional patients were excluded
because we were unable to obtain sufﬁcient blood for
PCT analysis, while 25 patients were excluded for the
following reasons: prematurity (n = 7), preexisting
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conditions such as ventriculoperitoneal shunts (n = 4),
obvious focus of infection such as cellulitis (n = 3), did
not meet age criterion (n = 2), history of antibiotic use
(n = 2), and did not meet inclusion criteria or were not
evaluated for SBI by the ED physician (n = 7).
Among the ﬁnal analytic population of 226 patients,
the mean (SD) age was 10.5 (8.4) months (range = 1
to 35 months) with slightly more than one-half being
female (58%) and 88.5% being of non-white race. A
total of 224 of 226 (99%) patients had WBC counts per-
formed. Blood cultures were obtained from all 226 chil-
dren, urine cultures from 219 (96.9%), and CSF cultures
from 31 (13.7%). A total of 132 children (58.4%) received
chest radiographs. Nineteen of 226 (8.4%) patients had
all of the following studies: blood culture, urine culture,
chest radiograph, CSF culture, and WBCs. The overall
prevalence of SBI was 13.3% (30 patients). Of the 30
patients with SBIs, four (13.3%) had only positive blood
cultures; 18 (60.0%) had only positive urine cultures,
eight (26.6%) had only positive chest radiographs, and
one (3.0%) had a positive CSF culture (this patient also
had a positive blood culture).
Results from the simple comparison analysis indicated
that patient demographics and presenting symptoms
stratiﬁed by SBI status were not signiﬁcantly different
(Table 1). There was no signiﬁcant difference in the
duration of fever or temperature at presentation to the
ED between patients with and those without SBIs.
Patients with SBIs had higher presenting mean WBC
counts, absolute band counts, and ANCs than non-SBI
patients. On average, those with SBIs had 2.5 ng/mL
mean higher PCT level than those without SBIs.
The diagnostic accuracies of the screening tests and
biomarkers at their predetermined cutoff values in addi-
tion to the cutoff values determined by AUC analyses
are demonstrated in Table 2. The WBC count at a pre-
determined threshold of 15 9 109 cells/L had the highest
sensitivity at 56.7%, followed by PCT at a threshold
of >0.5 ng/mL (53.3%) and ANC at a threshold of 10
9 109 cells/L (46.7%). The absolute band count, at a
threshold of 1.5 9 109 cells/L, correctly identiﬁed only
20.0% of patients with SBIs. The speciﬁcity of the tests
ranged from 76.3% to 93.3%; the PCT at a threshold
of >0.5 ng/mL correctly identiﬁed approximately 90% of
the non-SBI patients. The PCT at a threshold of >0.5 ng/
mL had the highest positive likelihood ratio (LR) of 5.39,
followed by the ANC, absolute band count, and WBC
count. PCT also had the lowest negative LR (–LR; 0.52),
followed by the WBC count, ANC, and absolute band
count.
We also assessed the diagnostic properties of the four
biomarkers using ROC curves (Figure 1). The AUC for
PCT was the largest (0.80, 95% CI = 0.71 to 0.89) fol-
lowed by the WBC count (0.76, 95% CI = 0.66 to 0.86),
ANC (0.73, 95% CI = 0.63 to 0.84), and absolute band
count (0.67, 95% CI = 0.55 to 0.78). When the four
curves were compared, there was an overall difference
between the AUCs (p < 0.0001). The optimal thresholds,
determined by maximizing both the sensitivity and the
speciﬁcity on ROC analysis, for each biomarker in pre-
dicting SBI were as follows: WBC count > 19 9 109
cells/L, absolute band count > 1.8 9 109 cells/L, ANC
> 13 9 109 cells/L, and PCT > 0.6 ng/mL.
The data ﬁt the multivariable logistic regression
model well, with a chi-square of 5.02 (p = 0.76) for the
Hosmer-Lemeshow goodness-of-ﬁt test and R2 = 0.407
(p < 0.01; Table 3). When evaluating the predictor vari-
ables in their continuous forms in the multivariable
analysis, apart from age, the PCT and the absolute band
count were the two screening tests that were indepen-
dently associated with SBI (Table 3). This analysis was
adjusted for the effects of age, temperature, and the
other blood screening laboratory tests. None of the
other commonly used blood screening tests were
Table 1
Demographic, Clinical, and Laboratory Characteristics of Enrolled Patients (Stratified by SBI Status)*
Characteristic
All Patients,
N = 226
SBI Negative,
n = 196
SBI Positive,
n = 30
Difference in Means or
Percentages (95% CI)
Demographics
Age (months) 10.5 (8.4) 10.6 (8.4) 9.6 (8.1) –1.0 (–2.2 to 4.3)
% < 3 months 43 (19.0) 38 (19.4) 5 (16.7) –2.7 (–17.1 to 11.7)
Male sex (%) 95 (42.0) 88 (44.9) 7 (23.3) –21.6 (–4.9 to –38.3)
Nonwhite race (%) 200 (88.5) 174 (88.8) 22 (86.7) –2.1 (–15.0 to 10.8)
Presenting symptoms
Duration of fever (days) 1.9 (1.5) 1.8 (1.4) 2.5 (2.1) –0.7 (–1.2 to –0.1)
Presenting temperature (°C) 39.3 (0.9) 39.3 (0.8) 39.4 (0.9) 0.1 (–0.4 to 0.2)
Test results
WBC count (9109 cells/L) 12.4 (6.3) 11.5 (5.3) 18.6 (8.6) 7.1 (4.8 to 9.3)
ANC (9109 cells/L) 6.3 (4.6) 5.6 (3.8) 10.6 (6.7) 5.0 (3.4 to 6.7)
Absolute band count (9109 cells/L) 0.42 (0.70) 0.35 (0.60) 0.90 (1.10) 0.55 (0.15 to 0.95)
PCT (ng/mL) 0.7 (2.3) 0.4 (0.8) 2.9 (5.6) 2.5 (0.4 to 4.6)
Treatments
Antibiotics administered in ED 134 (59.3) 106 (54.1) 28 (93.3) 39.2 (27.9 to 50.5)
Antibiotics prescribed at discharge 65 (29.0) 54 (27.8) 11 (36.7) 8.9 (–9.5 to 27.3)
ED disposition
Admitted to hospital 55 (24.3) 36 (18.4) 19 (63.3) 44.9 (26.8 to 63.0)
Data are reported as mean (SD) or number (%).
ANC = absolute neutrophil count; PCT = procalcitonin; SBI = serious bacterial infection; WBC = white blood cell.
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independently associated with SBI, after adjusting for
the PCT.
As it is empirical that it would be difﬁcult to identify a
blood test that was as accurate as the urinalysis to diag-
nose UTI, we compared PCT at a threshold of 0.5 ng/mL
versus a positive urinalysis as a screen for UTI. As
anticipated, the urinalysis as a screening test performed
better than PCT among patients with UTIs. After remov-
ing non-UTI SBIs from the database, there were 182 of
226 (80.5%) patients with all three tests: urinalysis, urine
culture, and PCT performed. Forty-six of the 182 (25%)
patients had positive urinalyses, and 14.2% (26/182) had
PCT levels above the threshold of 0.5 ng/mL. For a posi-
tive urinalysis, sensitivity was 81.25% (95% CI = 54.34%
to 95.73%), speciﬁcity was 80.12% (95% CI = 73.23% to
85.90%), positive likelihood ratio (+LR) was 4.09 (95%
CI = 2.78 to 6.01), and negative likelihood ratio (–LR)
was 0.23 (95% CI = 0.08 to 0.65), while for PCT above
0.5 ng/mL, sensitivity was 43.75% (95% CI = 19.83% to
70.08%), speciﬁcity was 88.55% (95% CI = 82.70% to
92.96%), +LR was 3.82 (95% CI = 1.9 to 7.68), and –LR
was 0.64 (95% CI = 0.41 to 0.98) for detecting UTI. Fur-
thermore, we evaluated the performance of PCT in the
regression model with the 77 patients who had either
positive urinalyses (n = 49) or missing urinalyses
(n = 28) removed from the analysis. PCT was the only
marker that was independently associated with SBI
(PCT OR = 1.57 for each ng/mL increase, 95% CI = 1.05
to 2.34, p = 0.027). Age, temperature, WBC, ANC, and
absolute band count were not independently associated
with SBI in this analysis.
Because some patients with lobar pneumonias may
nevertheless have viral infections as their etiology, we
performed a separate multivariable analysis to test the
performance of PCT on patients with SBI excluding
those diagnosed with pneumonia (eight patients among
30 SBI were diagnosed as pneumonia and were there-
fore removed). Age, absolute band count, and PCT were
all independently associated with SBI, with PCT demon-
strating the highest OR (1.42, 95% CI = 1.01 to 2.00;
Table 4).
DISCUSSION
In this study, we found that the serum PCT was supe-
rior to traditional laboratory screening tests for detect-
ing SBIs in febrile infants and young children without
obvious sources of infection presenting to the ED. In
addition, a PCT cutoff value of 0.6 ng/mL performed
better than the more traditional cutoff value of 0.5 ng/
mL in predicting SBI. In the multivariable logistic
regression analysis, young age, the absolute band
count, and PCT were all independently associated with
SBI. The incidence of SBI is higher in younger febrile
infants compared to older febrile children, consistent
with prior research.16 PCT appears to be more accurate
as a screening test for SBI than other traditional blood
screening tests, demonstrated by the greater AUC for
PCT. Although we also found the absolute band count
to also be signiﬁcant in both the bivariate and the multi-
variable analyses, the utility of absolute band counts in
identifying children with SBI has been questioned by
some,17–19 while others have demonstrated that absolute
band counts may vary between laboratories.20
The management of febrile infants and young chil-
dren without obvious foci of infection remains a clinical
conundrum for clinicians. To minimize the risk of misdi-
agnosing a child who in fact has an SBI, many ED prac-
titioners rely on published guidelines and screening
diagnostic tests, including lumbar punctures, particu-
larly in the youngest infants 90 days of age and youn-
ger.1,21 Considerable debate exists in the evaluation of
these infants, with much controversy regarding the
published guidelines because: 1) studies pertaining to
Table 2
Diagnostic Parameters of Screening Tests for SBI*
Biomarker Sensitivity (95% CI) Specificity (95% CI) +LR (95% CI) PPV† (95% CI) –LR (95% CI) NPV† (95% CI)
WBC count (9109 cells/L)
>15.0† 56.7(37.7–74.0) 76.3(69.6–82.0) 2.39(1.60–3.57) 0.27(0.17–0.40) 0.57(0.38–0.86) 0.92(0.86–0.95)
>19.0§ 46.7(28.8–65.4) 90.2(84.9–93.8) 4.76(2.69–8.45) 0.15(0.11–0.20) 0.59(0.42–0.83) 0.85(0.80–0.89)
ANC (9109 cells/L)
>10.0† 46.7(28.8–65.4) 88.1(82.5–92.2) 3.94(2.29–6.77) 0.38(0.23–0.55) 0.61(0.43–0.85) 0.91(0.86–0.95)
>13.0§ 30.0(15.4–49.6) 94.3(89.8–97.0) 5.29(2.40–11.69) 0.45(0.24–0.68) 0.74(0.59–0.94) 0.90(0.84–0.93)
Absolute band count (9109 cells/L)
>1.5† 20.0(8.0–39.1) 93.3(88.6–96.2) 2.99(1.23–7.25) 0.32(0.14–0.56) 0.86(0.72–1.03) 0.88(0.83–0.92)
>1.8§ 20.0(8.4–39.1) 96.4(92.4–98.4) 5.54(2.00–15.38) 0.06(0.03–0.10) 0.83(0.69–0.99) 0.94(0.90–0.97)
PCT (ng/mL)
>0.5† 53.3(34.6–71.2) 90.1(84.8–93.8) 5.39(3.13–9.27) 0.46(0.29–0.63) 0.52(0.35–0.76) 0.93(0.88–0.96)
>0.6§ 51.6(33.4–69.4) 92.7(87.8–95.8) 7.04(3.83–12.94) 0.13(0.09–1.89) 0.52(0.36–0.75) 0.86(0.81–0.91)
ANC = absolute neutrophil count; AUC = area under the receiver operating characteristic curve; +LR = positive likelihood ratio;
–LR = negative likelihood ratio; NPV = negative predictive value; PCT = procalcitonin; PPV = positive predictive value; SBI = seri-
ous bacterial infection; WBC = white blood cell.
*All values above and below the cutoff points are considered as screening positive for SBI and screening negative for SBI,
respectively.
†Pretest probability used in computing the posttest positive predictive values were 13.3% based on the prevalence of SBI (30/
226) observed in this study.
§All values above and below optimal cutoff points determined by the AUC (Figure 1) are considered as screening positive for
SBI and screening negative for SBI.
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febrile infants have been conducted in a single or small
groups of academic centers1; 2) studies have used retro-
spective designs, different inclusion criteria (e.g., with
respect to age and temperature cutoffs to deﬁne fever),
and different laboratory criteria for distinguishing high-
risk versus low-risk infants4; and 3) solid evidence ques-
tioning the discriminatory ability of commonly used
screening tests such as WBC and ANC in the youngest
febrile infants.21
The availability of a biomarker that could accurately
and rapidly identify SBI in febrile infants and children
without obvious source would frequently obviate the
need for invasive procedures such as lumbar punctures
and reduce the use of empirical antibiotics and hospital-
ization and would be of signiﬁcant importance to
patients, their families, and clinicians. Prior studies on
the accuracy of PCT in screening febrile infants and
children for SBI in the ED setting have revealed incon-
sistent results. One study demonstrated that PCT was
the single best laboratory screening test when com-
pared to IL-6, IL-8, and IL-1 receptor antagonists and
CRP in 124 well-appearing febrile infants 7 days to
36 months of age.8 Similarly, a large multicenter study
of 445 well-appearing febrile infants 1 to 36 months old
also concluded that PCT was superior to the CRP and
other routinely used laboratory screening tests for dis-
tinguishing those with viral and bacterial infections.6 In
contrast, the ﬁndings of another study of 72 febrile chil-
dren 1 to 36 months of age suggest the diagnostic accu-
racy of PCT, CRP, and WBC are comparable to clinical
scoring (Yale Observational Scale)22 and do not change
posttest probabilities to a clinically useful extent.23 In a
Figure 1. Receiver operating characteristic curve of PCT and three blood count biomarkers for SBI. Note: The optimal cutoff points
were determined by observation while maximizing both sensitivity and specificity. The units for PCT are in ng/ml, while white
blood cell count, absolute neutrophil count, and absolute band counts are in cells/mm3
PCT = procalcitonin; SBI = serious bacterial infection.
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different study of febrile infants, although PCT and CRP
were found to be better markers than the WBC in iden-
tifying SBI in febrile infants, the authors concluded that
the CRP may be the most convenient for use in the ED
setting.24 Finally, two evidence-based reviews of pub-
lished studies on the use of PCT as a screening test for
SBI in febrile children younger than 3 years of age con-
cluded that PCT is still not sufﬁciently sensitive to be
used as a single screening tool to exclude the possibility
of SBI.25,26 The direct comparison of the current study
with those mentioned above is difﬁcult because of the
study heterogeneity with regard to inclusion criteria,
screening test thresholds, and deﬁnitions of SBI, among
others.
There remain important, pressing issues regarding
the evaluation of young febrile children. The successful
introduction of conjugate pneumococcal vaccines has
dramatically altered the evaluation of febrile children
older than 3 months of age in the past two decades.27,28
Further research should be focused on the effect
of novel biomarkers, rapid turnaround identiﬁcation of
pathogens, and DNA/RNA expression patterns to
distinguish febrile infants with SBIs from those with
viral infections. Additionally, the test characteristics of
PCT need to be studied in substantially larger numbers
of febrile children who have bacteremia and/or menin-
gitis. Two recent studies on the usefulness of PCT as a
biomarker in young febrile infants (<90 days of age) are
notable.29,30 In one of these studies, the test characteris-
tics of PCT, CRP, and WBC counts were compared in
347 febrile infants < 90 days of age (who had an SBI
rate of 23.6%).29 The investigators demonstrated that
although PCT and CRP had similar AUCs (0.77 and
0.79); both these variables were better predictors than
the WBC count (AUC = 0.67). In a subset of infants
with more invasive bacterial infections (sepsis, bactere-
mia, bacterial meningitis) in that study, the diagnostic
value of PCT (AUC = 0.84) was higher than that of the
CRP (AUC = 0.68). In another study, the investigators
studied the accuracy of PCT in 234 febrile infants youn-
ger than 90 days of age (with a 12.8% SBI rate) and
demonstrated that mean PCT levels for those infants
with SBIs was signiﬁcantly higher than for those with-
out SBIs (2.21 ng/mL vs. 0.38 ng/mL, AUC 0.82) and
concluded that PCT had better test characteristics than
any other biomarker.30 To more deﬁnitively evaluate
the role PCT testing in this patient population, however,
we suggest that an adequately powered multicenter
prospective study of young febrile infants be conducted
to determine the test characteristics and marginal bene-
ﬁt of PCT over routinely used screening tests.
LIMITATIONS
As this was an observational study of a convenience
sample of febrile infants and children, without a stan-
dardized evaluation and management protocol enforced
at the participating sites, we recognize that there may
have been a selection bias of the study population. Vari-
ation in the evaluation of febrile children based on
patient age, degree of fever, and training of the ED phy-
sician has been well described previously.1 We did not
document clinical scores (such as the Yale Observation
Scale score22) on all patients because this was not a part
of institutional practice; however, every enrolled patient
was documented to be well-appearing on the ED physi-
cians’ initial evaluations. There were also relatively
few patients with bacteremia, and more with UTIs.
Although we demonstrated that the urinalysis was a
better screening test for UTI than was PCT, the PCT
nevertheless was a signiﬁcant predictor of UTI in the
multivariable analysis when patients with positive uri-
nalyses were removed from the analysis. This highlights
the potential utility of PCT as a screening test for UTI in
patients with undifferentiated sources of fever from
whom urine is not initially obtained. We also did not
compare the test characteristics of PCT to that of CRP
because the latter test is not routinely performed at the
four participating institutions. Finally, we used the ED
attending or radiologist interpretation of chest radio-
graphs for deﬁnition of pneumonia, and it is possible
that we could have missed patients with pneumonias
who had negative radiographs or included those with
viral etiologies for their pneumonias. Despite removing
Table 3
Multivariable Logistic Regression Analysis of Predictors of
Serious Bacterial Infection (n = 226)
Predictor Variable
Adjusted OR
(95% CI) p-value
Age (months) 0.90 (0.82–0.98) 0.015
Presenting
temperature (°C)
1.21 (0.66–2.20) 0.537
PCT (ng/mL) 1.67 (1.12–2.49) 0.013
WBC count (9109 cells/L) 1.01 (0.99–1.02) 0.526
ANC (9109 cells/L) 1.01 (0.99–1.04) 0.199
Absolute band count
(9109 cells/L)
1.07 (1.01–1.14) 0.018
Model fit
Hosmer-Lemeshow test v2 = 5.02 0.76
Variance explained R2 = 0.407
(maximum re-scaled)
<0.01
The ANC and absolute band count were divided by 100 to
rescale the measurement range for robust statistical analysis.
ANC = absolute neutrophil count; PCT = procalcitonin;
WBC = white blood cell.
Table 4
Multivariable Logistic Regression Analysis of Predictors of
Serious Bacterial Infection (Patients Diagnosed With Pneumonia
Removed; n = 218)
Predictor Variable
Adjusted
OR (95% CI) p-value
Age (months) 0.87 (0.78–0.96) 0.01
Presenting temperature (°C) 1.39 (0.68–2.85) 0.37
PCT (ng/mL) 1.42 (1.01–2.01) 0.04
WBC count (9109 cells/L) 1.0 (0.99–1.02) 0.62
ANC (9109 cells/L) 1.01 (0.99–1.04) 0.19
Absolute band count
(9109 cells/L)
1.10 (1.03–1.18) 0.004
ANC = absolute neutrophil count; PCT = procalcitonin;
WBC = white blood cell.
ACADEMIC EMERGENCY MEDICINE • February 2014, Vol. 21, No. 2 • www.aemj.org 177
patients with pneumonia in a subanalysis, however,
PCT was independently associated with SBI.
CONCLUSIONS
Procalcitonin appears to be a more accurate marker
than the white blood cell count, the absolute neutrophil
count, or the absolute band count in identifying young
febrile infants and children with serious bacterial infec-
tions. Further study on a larger cohort is required to
more deﬁnitively determine the marginal beneﬁt of pro-
calcitonin over traditionally used screening laboratory
tests in these patients.
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